DDInter602 DDInter927
Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate control, rhythm control, prevention of thromboembolic events, and treatment of the underlying disease. Similar to [amiodarone], dronedarone is a multichannel blocker that works to control rhythm and rate in atrial fibrillation. It meets criteria of all four Vaughan Williams antiarrhythmic drug classes by blocking sodium, potassium, and calcium ion channels and inhibiting β-adrenergic receptors.[A34604,L8699] Dronedarone is a related benzofuran compound to amiodarone but its chemical structure lacks iodine moieties which are associated with amiodarone-induced thyroid problems.[A34604,T28] Additionally
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Dronedarone {u} (Compound) resembles {v} (Compound) Ibutilide
Dronedarone {u} (Compound) binds {v} (Gene) CACNA1F
Dronedarone {u} (Compound) causes {v} (Side Effect) Skin disorder
Dronedarone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Dronedarone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Dronedarone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bisacodyl
Dronedarone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Dronedarone {u} may lead to a major life threatening interaction when taken with {v} Gilteritinib
Dronedarone {u} may lead to a major life threatening interaction when taken with {v} Sorafenib
Dronedarone (Compound) resembles Ibutilide (Compound)
Dronedarone (Compound) binds CACNA1F (Gene)
Dronedarone (Compound) causes Skin disorder (Side Effect)
Dronedarone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Dronedarone may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Dronedarone may lead to a major life threatening interaction when taken with Gilteritinib
Dronedarone may lead to a major life threatening interaction when taken with Sorafenib